You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 9,840,505

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,840,505 protect, and when does it expire?

Patent 9,840,505 protects COPIKTRA and is included in one NDA.

This patent has forty patent family members in twenty-three countries.

Summary for Patent: 9,840,505

Scope and claims summary:

Title:	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Abstract:	Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Inventor(s):	Ren; Pingda (San Diego, CA), Martin; Michael (San Marcos, CA), Isbester; Paul (Castleton, NY), Lane; Benjamin S. (Lynnfield, MA), Kropp; Jason (Westford, MA)
Assignee:	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/016,117
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,840,505

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	⤷ Subscribe
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)	⤷ Subscribe
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)	⤷ Subscribe
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,840,505

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084824	⤷ Subscribe
Argentina	117467	⤷ Subscribe
Australia	2012205669	⤷ Subscribe
Australia	2015258280	⤷ Subscribe
Brazil	112013017670	⤷ Subscribe
Canada	2824197	⤷ Subscribe
Chile	2013002007	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.